Rapamycin/DiR Loaded Lipid-Polyaniline Nanoparticles for Dual-Modal Imaging Guided Enhanced Photothermal and Antiangiogenic Combination Therapy by Wang, Jinping et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jconrel.2016.07.005
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Wang, J., Guo, F., Yu, M., Liu, L., Tan, F., Yan, R., & Li, N. (2016). Rapamycin/DiR Loaded Lipid-Polyaniline
Nanoparticles for Dual-Modal Imaging Guided Enhanced Photothermal and Antiangiogenic Combination
Therapy. JOURNAL OF CONTROLLED RELEASE, 237, 23-34. DOI: 10.1016/j.jconrel.2016.07.005
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
  	

Rapamycin/DiR Loaded Lipid-Polyaniline Nanoparticles for Dual-Modal
Imaging Guided Enhanced Photothermal and Antiangiogenic Combination
Therapy
Jinping Wang, Fang Guo, Meng Yu, Li Liu, Fengping Tan, Ran Yan,
Nan Li
PII: S0168-3659(16)30430-8
DOI: doi: 10.1016/j.jconrel.2016.07.005
Reference: COREL 8362
To appear in: Journal of Controlled Release
Received date: 25 January 2016
Revised date: 12 June 2016
Accepted date: 2 July 2016
Please cite this article as: Jinping Wang, Fang Guo, Meng Yu, Li Liu, Fengping Tan,
Ran Yan, Nan Li, Rapamycin/DiR Loaded Lipid-Polyaniline Nanoparticles for Dual-
Modal Imaging Guided Enhanced Photothermal and Antiangiogenic Combination Ther-
apy, Journal of Controlled Release (2016), doi: 10.1016/j.jconrel.2016.07.005
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
Rapamycin/DiR Loaded Lipid-Polyaniline Nanoparticles for 
Dual-Modal Imaging Guided Enhanced Photothermal and 
Antiangiogenic Combination Therapy 
Jinping Wang
 a
, Fang Guo
 a
, Meng Yu
 a
,
 
Li Liu
a
,
 
Fengping Tan
 a
, Ran Yan
 b, 
**, Nan Li
 a, 
* 
a 
Tianjin Key Laboratory of Drug Delivery & High-Efficiency, School of Pharmaceutical Science 
and Technology, Tianjin University, Tianjin, PR China. 
b 
Division of Imaging Sciences and Biomedical Engineering, King’s College London, London, 
United Kingdom. 
 
 
 
 
 
 
**Co-corresponding author at: Division of Imaging Sciences,The Rayne Institute, King's College 
London, 4th Floor, Lambeth Wing St Thomas’ Hospital, London SE1 7EH, United Kingdom. 
E-mail address: ran.yan@kcl.ac.uk 
Tel: + 44-207-6792344 
*Corresponding author at: School of Pharmaceutical Science and Technology, Tianjin University, 
300072, Tianjin, PR China. 
Tel.:+86-022-27404986 
E-mail address: linan19850115@163.com 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
Abstract 
Imaging-guided photothermal therapy (PTT) has promising application for 
treating tumors. Nevertheless, so far imaging-guided photothermal drug-delivery 
systems have been developed with limited success for tumor chemo-photothermal 
therapy. In this study, as the proof-of-concept, a stimuli-responsive tumor-targeting 
rapamycin/DiR loaded lipid-polyaniline nanoparticle (RDLPNP) for dual-modal 
imaging-guided enhanced PTT efficacy is reported for the first time. In this system, 
polyaniline (PANI) with π-π electronic conjugated system and effective photothermal 
efficiency is choosed as the appropriate model receptor of fluorescence resonance 
energy transfer (FRET), and loaded cyanine probe (e.g., 
1,1-dioctadecyl-3,3,3,3-tetramethylindotri-carbocyanine iodide, DiR) acts as the 
donor of near-infrared fluorescence (NIRF). In addition, rapamycin (RAPA), which is 
used as the antiangiogenesis chemotherapeutic drug, can cutdown the tumor vessels 
and delay tumor growth obviously. After intravenous treatment of RDLPNPs into 
Hela tumor bearing mice, fluorescent (from DiR) and enhanced photoacoustic (from 
DLPNPs) signals were found in tumor site over time, which reached to peak at the 6 h 
time point. After irradiating with an NIR laser, a good anti-tumor effect was observed 
owing to the enhanced photothermal and antiangiogenic effect of RDLPNPs. These 
results show that the multifunctional nanoparticle can be used as a promising 
imaging-guided photothermal drug delivery nanoplatform for cancer therapy.  
Keywords: Rapamycin, Lipid-polyaniline nanoparticles, Enhanced photothermal 
therapy, Antiangiogenesis, Imaging-guided therapy 
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1. Introduction 
In the past decade, great eﬀorts have been given to multifunctional nanomaterials 
that combine diagnostic and therapeutic functions for high-efficient and low-toxicity 
anticancer therapy. In particular, real-time imaging guided photothermal therapy (PTT) 
mediated by inorganic or organic nanoparticles responsive to near-infrared (NIR, λ = 
700-1100 nm) light through conversion of photo energy into heat has attracted 
increasing interest due to its simplicity, safety, noninvasiveness as well as targeting 
and remote-control properties [1-4]. Therefore, studies in recent years have been 
designed to identify the most applicable PTT methods, extensively focusing on 
aspects such as controlling the shape of PTT agents [5, 6], developing novel materials 
[7-9], the fabrication process [10], using hybridization methods to enhance the PTT 
effect [11], and incorporating photoacoustic (PA) or fluorescence imaging reagents 
[12-14] and improving drug loading capabilities and release attributes [15].  
Among various PTT agents, organic nanomaterials have attracted more 
attentions because the inorganic PTT materials usually are nonbiodegradable with 
cytotoxic properties and generally would remain in the body for long periods of time 
after systemic administration [16]. As an organic material, polyaniline (PANI) is 
potentially one of the most useful conductive polymers [17-20]. A distinct feature of 
PANI is that it can switch from the form of emeralidine base (EB) to emeralidine salt 
(ES) by doping protonic acids, alkali ions, or transition metals and so on ect., which 
can lead to strong NIR absorption and high conductivity [21]. Until very recently, 
several studies have reported that PANI nanoparticles can convert NIR light to thermo 
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energy. Thus, they can act as potential photothermal agents [21-23]. However, PANI 
nanoparticles alone have limited applications in cancer diagnosis and therapy due to 
low target to background contrast and poor tumor uptake [22, 24]. Therefore, 
additional effort is still needed to develop PANI nanomaterials with adequate PTT 
properties for efficient cancer therapy. 
In spite of recent positive progress in the development of diverse photothermal 
materials [25, 26],
 
there are only a few solutions to enhance the intrinsic photothermal 
property of PTT agents due to the lack of strategies to regulate their photothermal 
conversion efficiency except dimensions and concentrations [27, 28]. So far, the 
well-engineered photothermal agents for improving imaging guided PTT have not 
been reported [29-34], though stimuli-responsive nanomaterials are widely employed 
in the functional drug delivery system. Therefore, it is highly necessary to develop a 
multifunctional photothermal agent using as an efficient drug delivery system to 
improve the intrinsic photothermal performance and drug release capacity for 
imaging-guided enhanced PTT and chemotherapy. 
Recently, great interests have been devoted to the NIR fluorescent dyes and their 
nanostructures for imaging guided PTT applications [35-41]. One representative 
example is the 1,1-dioctadecyl-3,3,3,3-tetramethylindotri-carbocyanine iodide (DiR) 
that is a lipophilic fluorescent probe (a subclass of cyanine dyes) with strong 
absorption in the NIR region and negligible cytotoxicity at low concentration suitable 
for both in vivo fluorescence imaging and photothermal treatment [42-44]. DiR has 
been developed as a particularly promising photothermal candidate because it can 
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convert absorbed fluorescent energy into heat via the non-radiative transition under 
the NIR laser irradiation. In addition, this type of cyanine dyes can also convert 
near-infrared fluorescence (NIRF) into thermal energy via radiative transition upon 
photoirradiation [14]. Due to this distinctive characteristic, the photothermal 
conversion efficiency of DiR is remarkably enhanced. Interestingly, PANI with π-π 
electronic conjugated system and broad NIR absorbance can act as a model receptor 
to receive the NIFR from a donor fluorescent probe such as DiR due to the 
fluorescence resonance energy transfer (FRET) effect
 
[45]. Therefore, NIRF from DiR 
would be converted into additional thermal energy when coupled with the PANI 
nanoparticles to enhance their overall PTT. 
In this work, as proof-of-concept, we designed a novel folic acid (FA)-grafted 
DiR loaded lipid-PANI nanoparticle (denoted as DLPNP) exhibiting FRET effect 
between DiR and PANI (Scheme 1a and b). The lipid-PANI nanoparticles with π-π 
electronic conjugated system and broad NIR absorbance is selected as a fluorescence 
resonance energy receptor and delivery system owing to its effective photothermal 
conversion efficiency, targeting ability and high drug loading capacity. DiR not only 
acts as the fluorescence resonance energy donor but also is used for NIR fluorescence 
imaging. In order to obtain a multifunctional nanoplatform applied simultaneously for 
PTT, NIR fluorescence imaging, chemotherapy and rapamycin (RAPA) which could 
inhibit primary and metastatic tumor growth by antiangiogenesis was encapsulated 
into DLPNPs to form the RAPA/DiR loaded lipid-PANI nanoparticles (RDLPNPs) 
(Scheme 1a and b). RDLPNP is hypothesized to accumulate in the tumor in a time 
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dependent manner and provides PA imaging in the tumor site. Additionally, although 
RDLPNPs exhibited FRET effect upon irradiation, there will be still some residual 
NIRF signals providing the whole body biodistribution of the RDLPNPs. In this study, 
both enhanced PA and fluorescence imaging are able to detect significant RDLPNPs 
tumor uptake. 6 h after RDLPNPs intravenous injection (i.v.), both enhanced PA and 
fluorescent signals reached peak intensity in the tumor, indicating high tumor uptake 
of RDLPNPs. Subsequently, PTT was conducted on Hela tumor xenograft bearing 
mouse model using RDLPNPs and therapeutic response was monitored over 48 days. 
Comparing with control groups, eﬀective ablation of Hela tumors was achieved due to 
PTT induced RAPA release from the RDLPNPs. Our results proved the concept that 
RDLPNPs can be applied to the imaging guided combinational photothermal and 
chemo cancer therapy. 
2. Materials and methods 
2.1. Materials 
RAPA was purchased from Seuss Tai Biotechnology co., Ltd. (Tianjin, China). 
Aniline was obtained from Aladdin biological technology co., Ltd. (Shanghai, China). 
Dodecylbenzene sulfonic acid (DBSA) was purchased from Huawei Cree Chemical 
Industry (Beijing, China). 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine 
Iodide (DiR), and 3,3′-dioctadecyloxacarbocyanine perchlorate  (DiO) were obtained 
from Mellon, Biological Technology co., Ltd. (Dalian, China). 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
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glycol)-2000] (DSPE-PEG2000), and folic acid conjugated 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2
000] (FA-DSPE-PEG2000) were purchased from Shanghai Advanced Vehicle 
Technology Pharmaceutical Co., Ltd. (China). 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), 
4’,6-diamidino-2-phenylindole (DAPI), dimethyl sulfoxide (DMSO), calcein 
acetoxymethyl ester (Calcein AM), and propidium iodide (PI) were obtained from 
sigma-Aldrich Co. LLC. (Beijing, China). All chemicals were of analytical grade and 
used without further purification. 
2.2. Synthesis of emeraldine base PANI 
The emeraldine base PANI was synthesized by chemical oxidation 
polymerization in the presence of excess hydrochloric acid (HCl). Aniline monomer 
(0.2 mol) was added to the 1M HCl aqueous solution (300 mL). Consecutively, the 
polymerization process was conducted by dropwise addition of ammonium persulfate 
(0.05 mol) solution prepared in 1M HCl aqueous solution (200 mL) as an oxidant and 
kept at 4℃ for 6 hours. The precipitated polymer salt was recovered from the 
reaction vessel by filtration. The obtained green precipitate was re-dispersed in a 1M 
sodium hydroxide solution (500 mL). Then the deprotonated emeraldine base PANI 
was filtrated and re-dispersed in acetone (500 mL). After filtration and dried in a 
vacuum oven for 48 hours, the emeraldine base PANI was obtained as fine purple 
powder. The yield of emeraldine base PANI powder from aniline monomer was about 
69 wt%. The molecular weight of the synthesized emeraldine base PANI was 
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measured using gel permeation chromatography. In addition, absorbance of the 
prepared emeraldine base PANI was obtained using a Cary 60 UV-Vis 
spectrophotometer (Agilent, USA) and the characteristic bands were confirmed by 
Fourier-transform infrared spectroscopy (FT-IR, Varian, Excalibur™, USA). 
2.3. Preparation of RDLPNPs 
In this experiment, 5 mg of emeraldine base PANI (MW on a repeat unit basis = 
93.128 g/mol) and 35.05 mg of DBSA was dissolved in 5 mL of chloroform. The 
resulting mixture was stirred for 24h to afford the emeraldine salt PANI that possesses 
the optical-absorbance peak in the NIR region and the long chain alkyl group. After 
adding 1 mL of the resulting polymer solution (1 mg PANI/mL, 10.7 µmol on a repeat 
unit basis) in a separate vial containing 20 mL of chloroform, the RAPA, 0.1 mg DiR 
(0.1µmol, MW = 1013.39 g/mol), 35.2 mg of DPPC (48.0 µmol, MW = 734.06 
g/mol), 6.0 mg of DSPE- EG2000 (2.0 µmol, MW = 2805.5 g/mol), and 1.4 mg of 
FA-DSPE-PEG2000 (0.4 µmol, MW = 3246.9 g/mol) were added and dissolved by 
ultrasonication for 2 min. The molar ratio of the polymer to the lipid was about 1:5. 
Then the solvent was evaporated at 50℃ at 120 rpm under reduced pressure using 
rotary film evaporator (Rotavapor, Buchi, Germany). The residual solvent was 
completely removed in vacuum at room temperature in 12 h. Finally, the thin film that 
formed on the inner wall of the vial was shattered to nanoparticles by adding 5 mL of 
phosphate-buffered saline (PBS, pH 7.4) and ultrasonicated for 5 min. The obtained 
nanoparticles were purified by centrifugation (10,000 rpm for 5 minutes). After that, 
the suspension was further purified by ultra-ﬁltration through 100 kDa molecular 
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weight cut off (MWCO) ﬁlters. The obtained RDLPNPs could be readily re-dissolved 
in PBS and was stored for later use. The composition of all the nanoparticles used in 
this study was shown in the in Supporting Information Table S1. Drug loading 
efficiency and drug loading content were calculated according to the formulas: 
Drug loading efficiency =
amounts of drug in nanoparticles
total amount of drug
 × 100% 
Drug loading content =
amount of drug in nanoparticles
total weight of nanoparticles
 × 100% 
To prepare the DiO-labeled DLPNPs, DiO instead of RAPA was extra added into 
the chloroform solvent. The other preparation process was the same as described 
above. The obtained DiO-labeled nanoparticles were dispersed in Dulbecco's 
modified Eagle medium (DMEM) and kept at 4 °C under darkness for confocal laser 
scanning imaging.  
2.4. Characterization 
The dynamic diameter of DLPNPs was determined by a Zetasizer Nano-ZS 
(Malvern Instruments, UK). UV-Vis spectra was measured by a Cary 60 UV-Vis 
spectrophotometer (Agilent, USA) using quartz cuvettes with an optical path of 1 cm. 
Fluorescence spectra of free DiR (in order to increase the solubility of free DiR, 1% 
Tween-80 was added into the aqueous solution), DLPNPs, and LPNPs in the aqueous 
solution were investigated by an LS-55 fluorescence spectrophotometer 
(Perkin-Elmer). Thermal images were captured by an SC300 infrared camera (Fluke 
TiR, USA) and analyzed by Examine infrared image software. The excitation source 
was an 808 nm diode-pumped solid-state laser system (LASERGLOW Technologies, 
Shanghai, China). The morphology and structure of DLPNPs before and after laser 
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irritation were characterized by the JEM-100 CX (Jeol Ltd., Tokyo, Japan) 
transmission electron microscopy (TEM). 
2.5. In Vitro Release of RAPA from RDLPNPs  
The amount of RAPA was measured by high performance liquid chromatography 
(HPLC) (Waters Corp., Milford, MA), using CLC-ODS-18 column (5 cm, 4.6 × 150 
mm; Waters Corp., Milford, MA) maintained at 35 ℃,with an ultraviolet detector at 
287 nm. An isocratic mobile phase of 10% water in 90% methanol (v/v) was used 
with a flow rate of 1 mL min
-1
. The injection volume was 10 μL, and the retention 
time was about 5 min. 
The drug release experiments were performed using the dialysis technique. An 
NIR laser with the wavelength of 808 nm (1.5 W) was employed in this work. 
RAPA-loaded nanoparticles (1 mL) with a final RAPA concentration of 0.72 mg/mL 
were placed into a dialysis tube with a molecular weight cut off of 3000 Da and 
dialyzed against 40 mL of PBS at pH 5.0 or 7.4 with 0.5% Tween-80 in a thermo 
controlled shaker with a stirring speed of 500 rpm at 37 ℃. Samples of 200 μL were 
withdrawn at specified times. RAPA concentration was determined by HPLC. 
2.6. In Vitro Cellular Uptake and Chemo-photothermal Treatment 
The Hela human cervical cancer cell line (originally obtained from American 
Type Culture Collection) and human umbilical vein endothelial cells (HUVECs) 
(obtained from Procell life science and technology co., Ltd. Wuhan, China) were used 
and cultured under recommended conditions. In the in vitro cellular uptake 
experiments, Hela cells or HUVECs (4 × 10
5
 cells/well) were seeded into confocal 
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laser scanning microscopy (CLSM) culture dishes in 200 μL of medium for 24 h. For 
examining the intracellular uptake, Free DiO, free DiR or DiO labeled DLPNPs (100 
µL) were added into different dishes respectively. After 6 h incubation, with the whole 
cells reaching about 80% confluence, the cells were washed with PBS three times and 
fixed with 4% paraformaldehyde solution for 20 min. Subsequently, the nuclei were 
stained with DAPI solution (5 μg mL-1 in PBS) for 10 min. The cells were rinsed with 
PBS three times and observed by CLSM (Leica Microsystems, Heidelberg, Germany). 
The Hela cells or HUVECs incubated with DiO-DLPNPs for 2 h and 4 h were 
exposed to 1.5 W cm
-2
 808 nm laser irradiation for 3 min, respectively, and the cells 
were incubated for another 2 h and further investigated the photothermal influence on 
cellular uptake. 
The in vitro cytotoxicity was measured using a standard methyl 
thiazolyltetrazolium (MTT, Sigma Aldrich) assay. For the MTT assay, Hela cells or 
HUVECs were seeded into 96-well cell culture plates with the number of 8000 per 
well until adherent and then incubated at a series of RAPA concentrations (i.e., 0, 1, 
2.5, 5, 10, and 20 µg mL
−1
) with various formulations of RDLPNPs and free RAPA 
for 24 h. For the photothermal experiment, the cells were treated with an 808 nm laser 
at a power density of 1.5 W cm
−2 
for 3 min. The standard MTT assay was carried out 
to determine the cell viabilities. In addition, in order to compare the cytotoxicity of 
different formulations, Hela cells or HUVECs were seeded into 96-well cell culture 
plates with the number of 8000 per well until adherent and then incubated with 
equivalent concentrations of PBS, free RAPA, LPNPs, DLPNPs and RDLPNPs (final 
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RAPA concentration 5 μg/mL, final PANI concentration 25 μg/mL) for 24 h. After 6 h, 
the cells treated with free RAPA, LPNPs, DLPNPs and RDLPNPs were irritated by an 
808 nm laser at a power density of 1.5 W cm
−2 
for 3 min. After another 18 h 
incubation, the viability of cells was detected by the standard MTT assay. 
For examining the chemotherapy and photothermal ablation for Hela cells or 
HUVECs in vitro, the cells (1 × 10
6
 cells/well) were seeded into CLSM culture dishes 
in 200 μL of medium for 24 h. PBS and free RAPA (100 µL) were added into the 
dishes and then incubated for 6 h. The adherent cell solutions treated with DLPNPs 
and RDLPNPs were exposed to an 808 nm laser for 3 min with a power density of 1.5 
W cm
-2
. After removal of the medium, the adherent cells were washed with PBS for 
three times. Hela cells or HUVECs were incubated with calcein AM and PI solution 
for 15 min to separately stain the whole cells and dead cells. A green fluorescence 
color caused by calcein AM indicating viable cells and a red fluorescence color 
caused by PI indicating dead cells were then acquired by CLSM. 
2.7. Animal Experiments 
Female Balb/C mice were purchased from Beijing Huafukang Biological 
Technology Co. Ltd. and used under protocols approved by Tianjin University School 
of Pharmaceutical Science and Technology, Tianjin, China. Hela cells (1 × 10
6
) 
suspended in 200 μL of PBS were subcutaneously injected into the oxter of each 
female Balb/C mouse. After ∼10 days, the mice bearing Hela tumors were treated 
when the tumor volume reached ∼80 mm3. The mice were randomly divided into six 
groups (n = 5 per group) and treated under one of the following five experimental 
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conditions: i.v. injected with PBS only (PBS); i.v. injected with free RAPA only (Free 
RAPA); i.v. injected with RDLPNPs only (RDLPNPs); treated with LPNPs and 
exposed to the laser (LPNPs + NIR); treated with DLPNPs and exposed to the laser 
(DLPNPs + NIR); and treated with RDLPNPs and exposed to the laser (RDLPNPs + 
NIR). Tumor volumes were monitored every 2 days for 20 days. On day 8, major 
organs were collected after treatment and were formalin fixed and processed for 
routine hematoxylin and eosin (H&E) staining using standard methods. Images were 
collected using a Nikon light microscope (Nikon).  
2.8. In Vivo Imaging and Biodistribution Analysis 
In vivo fluorescent images of Balb/c mice were taken by using free DiR 
(dissolved in PBS with 10% ethanol) and DLPNPs. The mice were injected through 
the tail vein with 200 μL of free DiR and DLPNPs with the equivalent dose of 0.05 
mg/kg DiR. The images were obtained by the ex/in vivo imaging system (CRi, 
Woburn, MA) with a 748 nm excitation wavelength and a 780 nm filter to collect the 
fluorescence signals of DiR at 0, 2, 4, 6 and 12 h. The mice after in vivo imaging were 
sacrificed and the tumors, hearts, livers, spleens, lungs, kidneys were collected for 
imaging and semiquatitative biodistribution analysis. 
In vivo PA images of Balb/c mice were taken by using LPNPs and DLPNPs. The 
mice were injected through the tail vein with 200 μL of LPNPs and DLPNPs with the 
equivalent dose of 10 mg/kg PANI. After injection, PA images in the tumor sites were 
recorded on Vevo LAZR PAI System (808 nm) at 0, 2, 4, 6, and 12 h. Regions of 
interest (ROI) were drawn over the tumor, and the PA signal intensity was then carried 
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out using ImageJ. 
2.9. In Vivo Infrared Thermal Imaging 
Mice bearing Hela tumors treated with PBS, free RAPA, RAPA loaded LPNPs 
(RLPNPs), or RDLPNPs were irradiated with the 808 nm laser at power densities of 
1.5 W cm
-2
 for 5 min and simultaneously imaged by an infrared thermal camera 
(Infrared Cameras. Inc.). 
2.10. CD-31 Antibody Staining and Study of Nanoparticles' Penetration in Tumor 
After tumor therapy experiment was complete, mice were respectively 
administered with PBS, free RAPA, DLPNPs and RDLPNPs, with or without NIR 
laser and were sacrificed 24 h post intravenous administration. Tumor was rapidly 
frozen at -80℃.Then, the treated tumor samples were sliced with a cryostat 
microtome. In order to observe the vasculature, the sections were incubated with a 
1:250 dilution of CD-31 primary antibody at 4℃ overnight followed by incubation 
with Dylight 549-labeled secondary antibody (1:200) for 1 h at room temperature. 
The sections were also stained by DAPI and covered with a coverslip. The sections 
were observed using a confocal fluorescence microscope (Leica Microsystems, 
Heidelberg, Germany). Five randomly selected microscopic fields were quantitatively 
analyzed on ImageJ (National Institutes of Health). 
2.11. Statistical Analysis 
Results were expressed as mean ± standard deviation (SD). Two-tailed paired 
and unpaired Student’s t tests were used to determine differences within groups and 
between groups, respectively. P value <0.05 was considered statistically significant. 
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3. Results and discussion 
3.1. Characterization of the DLPNPs  
Polyaniline (PANI) was synthesized by using anilinium salts protonated by HCl 
and ammonium persulfate as an oxidant [46]. The chemical oxidative polymerization 
process was carried out at 4 ℃ for 6 hours to produce a dark-green precipitate, 
which was purified by washing with amounts of deionized water. This precipitate was 
dedoped by sodium hydroxide to obtain the purple polymer powder of emeralidine 
base PANI. The molecular weight of synthesized emeralidine base PANI was 5000 Da, 
as measured by gel permeation chromatography (polydispersity index: 1.2; Figure S1 
in the Supporting Information). In the UV-Vis absorption spectra of emeralidine base 
PANI in chloroform, charge transfer between quinoid and benzenoid rings was 
observed at 580 nm (Figure S2 a in the Supporting Information). Furthermore, the 
chemical structure of emeraldine base PANI was confirmed by the FTIR spectra: 1156 
cm
-1 
(N=Q=N vibrations: stretching vibrations of quinoid rings), 1301 cm
-1 
(aromatic 
C-N stretching), 1496 cm
-1
 (C=C and C=N stretching of benzenoid rings), and 1585 
cm
-1
 (C=C and C=N stretching of quinoid rings; Figure S2 b in the Supporting 
Information). Then, the synthesized purple powder was dissolved in chloroform and 
re-doped by DBSA to obtain the emeralidine salt PANI (dark-green solution) with the 
long chain alkyl group. After adding the phospholipids (DPPC, DSPE-PEG2000, 
FA-DSPE-PEG2000) and DiR to above solution, the NIR dye loaded phase-separated 
thin film of PANI and phospholipids was obtained by evaporating the chloroform. 
The thin film was broken by ultrasonication after adding PBS (pH 7.4) to form 
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DLPNPs. 
Transmission electron microscopy (TEM) image was used to detected the 
morphology of DLPNPs (Figure 1a). As shown in Figure 1c, the average size of 
DLPNPs was 140.6 nm with a polydispersity of 0.103. An intuitive comparison of 
DiR, PANI and DLPNPs was represented (Figure 1b). Free DiR and PANI were 
scarcely dispersed in water, whereas the as-prepared DLPNPs exhibited considerable 
water-solubility with a dark green color. To evaluate the stability, DLPNPs was 
dissolved in PBS and cell culture medium, respectively, and stored at 37 ℃ for 7 
days. As shown in Supporting Information Figure S3 and Table S2, the appearance, 
sizes, polydispersity index (PDI), and the zeta potentials had no dramatic change. 
Figure 1d showed the UV-vis absorption spectrum of LPNPs, DLPNPs suspensions in 
PBS and free DIR dissolved in methanol, respectively. DLPNPs exhibited the 
absorbance peak at 754 nm, and fluorescence peak at 780 nm, confirming the 
successful incorporation of DLPNPs (Figure 1d and 1 e). When the DiR was 
encapsulated into the LPNPs, DLPNPs exhibited a great increase of absorbance from 
600 nm to 810 nm (Figure 1d). In addition, such an increased absorption of DLPNPs 
in the NIR region ensured their potential application as the photothermal drug 
delivery carriers for NIR laser inducing chemo-photothermal therapy. To demonstrate 
that the attached dye fluorescence could be quenched by LPNPs via FRET, we 
measured the fluorescence intensities of DiR and DLPNPs. The DiR had showed 
strong ﬂuorescence intensity in the aqueous solution. When it was encapsulated into 
LPNPs (forming DLPNPs), however, the attached dyes’ fluorescence intensities 
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dropped significantly (Figure 1e). We further observed that DLPNPs had stronger 
fluorescence in methanol than that in water, suggesting that DLPNPs obviously 
quenched in aqueous solution, while recovered in methanol by reason of the high 
solubility of DiR in methanol (Figure S4 in the supporting information). Considering 
the observed dyes’ fluorescence quenching, the decreased fluorescence intensity could 
be due to FRET between DiR molecules and PANI.  
Considering that photostability greatly affected UV absorbance of cyanine dye, 
we investigated the ability of lipid-PANI nanoparticles to enhance the photostability 
of DiR. UV-Vis spectra showed that free DiR exhibited a decrease of absorbance 
under 808 nm photoirradiation within 10 min, which may due to its photobleaching 
(Figure 1f). DLPNPs only performed a little loss of absorbance under 754 nm 
photoirradiation during 10 min and still exhibited sufficient absorbance (Figure 1g). It 
indicated that LPNPs could significantly improve the photostability of DiR (Figure 
1g), which was beneficial to the generation of photothermal energy or fluorescence 
from DiR. In addition, the stability of loaded DiR in the DLPNPs was also 
investigated. Only a negligible amount of free DiR was found in the medium (Figure 
S5, Supporting Information), indicating the good stability of DLPNPs. 
In order to evaluate the enhanced photothermal effect of DLPNPs, we monitored 
the real-time temperature changes with NIR laser irradiation using the temperature 
gauge or infrared thermal imaging camera. Under the 808 nm laser irradiation at 1.5 
Wcm
-2
 for 5min, the maximal temperature of DLPNPs, LPNPs, and free DiR reached 
to 62.8, 57.0, 36.3 ℃, respectively, while the temperature of PBS only increased by 
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8.2 ℃ (Figure 1h and i). Such a variation of DLPNPs could increase temperature 
over 50 ℃ after a short period of photoirradiation, which would cause an irreversible 
thermal ablation of cancer cells [47].
 
Remarkably, the temperature increase by 
DLPNPs was around 5 ℃ higher than that of LPNPs indicating additional thermal 
energy was generated by the FRET effect between DiR and PANI. These results also 
demonstrated that the broad absorbance of PANI enabled its absorption of most of 
fluorescence in the NIR region, thus maximizing the conversion efficiency of NIRF 
into thermal energy. 
To investigate RAPA loading capacity of DLPNPs, different amounts of RAPA 
were loaded into PANI nanoparticles and loading efficiency was calculated (Figure 2a 
and b). When the amount of RAPA reached to 4.5 mg (the molar ratio of RAPA/PANI 
is 22.68), the drug loading efficiency decreased by 20%. Notably, less than 3.6 mg 
RAPA could be encapsulated into the DLPNPs. This was also the first time for RAPA 
encapsulation into DLPNPs, with much higher drug loading content than other current 
RAPA loaded formulations [48-50]. The drug release behavior of RDLPNPs and 
RLPNPs under different pH values were evaluated by dialyzing samples in either pH 
5.0 or 7.4 PBS with 0.5% Tween-80 (Figure 2c and Figure S6 in the supporting 
information). Within 24 h, about 22% of RAPA was released from the RDLPNPs at 
pH 5.0, compared with 15% of that at pH 7.4, owing to the protonation of the amino 
group in the PANI molecule which might slightly change the structure of 
nanoparticles, thus facilitating drug release under acidic pH environment. In addition, 
the release behavior of RLPNPs was similar to that of LPNPs at pH 7.4 or pH 5.0. 
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Since the phase transition temperature of DPPC was 41.2 ℃ [51], we hypothesized 
that local heating of the nanocarriers might induce increased thermal vibration of lipid 
chains and thus weakened the binding with drug molecules. To prove the 
photothermal effect of DLPNPs on the RAPA release from the nanoparticles, 
RDLPNPs in PBS solutions with 0.5% Tween-80 at pH 5.0 or 7.4 were irradiated 
using an NIR laser (1.5 W cm
-2
 for 3 min, at 2, 6 and 24 h, respectively). The released 
RAPA before and after 808 nm laser irradiation was collected and measured by HPLC, 
in comparison to the samples in the dark without laser irradiation (Figure 2c and d). 
During the first 24 h, 38.6% of RAPA was released from the RDLPNPs, and increased 
to 94% of RAPA could release within 96 h. The data indicated that RAPA release 
from the RDLPNPs could be triggered by an NIR laser, likely due to the loosening of 
lipid-PANI packing resulting from a rapid local temperature increase. However, the 
amount of RAPA release from the RLPNPs was smaller than that of RDLPNPs due to 
the weak photothermal effect of the LPNPs. More interestingly, such 
photothermal-response release processes would depend on the environmental pH 
value. Significant NIR-triggered burst release of RAPA from RDLPNPS was noticed 
under acidic pH (pH = 5.0). In contrast, limited RAPA release was observed under 
physiological pH (pH = 7.4) even after exposure to the NIR laser irradiation. While 
being stable without NIR-triggered drug release outside cells under pH 7.4, 
RDLPNPS might release drug under NIR laser irritation only after entering tumor 
cells, where the pH value was about 5.0, minimizing the unnecessary drug release 
before cell internalization of nanoparticles. 
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3.2. In Vitro Cellular Uptake and Chemo-photothermal Treatment 
To examine the intracellular uptake, DiO encapsulated DLPNPs were used for 
fluorescence detection (DiO was the substitute of RAPA). The subcellular localization 
of free DiO, free DiR, DiO-DLPNPs in Hela cells and HUVECs was investigated 
using confocal microscopy. After 6 h incubation with free DiO, only a little amount of 
DiO was observed in the nucleus of both Hela cells and HUVECs (Figure 3a). Despite 
there were still some residual DiR signals from DLPNPs in the Hela cells and 
HUVECs, the red signal from DLPNPs was weaker than that from free DiR, 
indicating that the NIFR was quenched owing to FRET from DiR to PANI. After 
treatment with the DiO-DLPNPs, however, both DiO and DiR signals of Hela cells 
were stronger than that of HUVECs. The increased cellular localization of DiO and 
DiR in Hela cells could be due to the highly overexpressed of FA receptors on Hela 
cells’ surface [52]. To further confirm the ability of those particles to target the FA 
receptor, the competitive binding of non-FA functionalized DLPNPs 
(Non-FA-DLPNPs) and DLPNPs to Hela cells or HUVECs was performed by adding 
excess of free folate (1 mM) to block folate receptor binding 1 h before treatment with 
nanoparticles, respectively. The results (Figure S8 b and c) suggested the cellular 
uptake of DLPNPs decreased significantly in the presence of free FA in Hela cells, 
becoming almost equivalent to that of non-FA functionalized DLPNPs. However, 
neither the presence or absence of free FA in the culture medium influenced the 
cellular uptake of DLPNPs by HUVECs. It was clear that the selectivity of DLPNPs 
to Hela cells was blocked by free FA. Notably, DiO-DLPNPs formulation with NIR 
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laser not only significantly increased the fluorescence signals of DiO in both Hela 
cells and HUVECs, but also facilitated them entry into the nuclei (Figure 3a). In 
previous reports from others, it has been revealed that a proper thermal heating could 
increase the cell membrane permeability without damaging cells, improving the 
intracellular delivery of drugs [53, 54]. In addition, the heat caused by NIR laser 
could also induce the thermal vibration of lipid chains of DiO-DLPNPs and thus 
released more DiO into the cells and nuclei. Considering these factors, it is not 
surprising that photothermal heating significantly increased the uptake of DiO in both 
Hela cells and HUVECs. 
Next, we tested the cell-killing efficacy of different RAPA formulations in vitro. 
In this study, Hela cells and HUVECs were incubated with free RAPA (dissolved in 
PBS containing 0.5% Tween-80) and RDLPNPs for 24 h, respectively. The RDLPNPs 
treated cells were irritated by an NIR laser (808 nm, 1.5 W cm
−2
, 3 min). The relative 
cell viabilities were measured by the MTT assay and the results were shown in Figure 
S7. It was found that greater cytotoxicity was induced by higher drug level. At the 
same drug concentration, it was noted that the RDLPNPs with or without NIR laser 
significantly decreased the cell survival rate than that of the free RAPA. These results 
were attributed to the enhanced intracellular RAPA concentration facilitated by the 
RDLPNPs-mediated cellular uptake. In addition, the cytotoxic effect of chemotherapy, 
photothermal therapy, and chemo-photothermal therapy on Hela cells and HUVECs 
treated with PBS, free RAPA, DLPNPs, or RDLPNPs was evaluated respectively 
(Figure 3b). Without NIR laser irradiation, the viability of Hela cells and HUVECs 
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treated with DLPNPs was maintained at high rate, confirming that the DLPNPs were 
virtually nontoxic to Hela cells and HUVECs. Treated with free RAPA (5 μg/mL), 
however, the cell viability of Hela cells and HUVEC was decreased to 68.3 and 
64.5%, respectively, indicating that the RAPA could inhibit the mammalian target of 
rapamycin (mTOR) pathway and lead to Hela cell and HUVEC death. In addition, the 
viability of Hela cells and HUVEC in the free RAPA plus NIR laser group was 
slightly lower than that in free RAPA group, revealing that free RAPA could not 
produce the photothermal effect under the NIR laser irradiation. Notably, upon NIR 
irradiation, the cytotoxicity of DLPNPs and RDLPNPs exhibited much pronouncedly 
increase than that of free RAPA. As the NIR laser irradiation alone did not lead to a 
decline in Hela cell and HUVEC viability, the observed increase in cytotoxicity could 
be attributed to the NIR irradiation-induced photothermal ablation and RAPA release 
mediated by RDLPNPs.  
Similar results were also observed in the fluorescence staining of live/dead cells, 
where most of Hela cells and HUVECs incubated with RDLPNPs plus NIR 
irradiation presented PI-positive staining due to extensive cell death (Figure 3c). The 
results could be attributed to the following two reasons: Firstly, RDLPNPs were 
presumably internalized by cells in a more effective FA receptors mediated manner, 
leading to (1) a higher intracellular RAPA concentration comparing with free RAPA; 
(2) sufficient amount of PANI which preserved a profound phototriggered ablation 
effect. Secondly, RDLPNPs with the NIR laser irradiation produced the photothermal 
heating, which induced more RAPA release from DLPNPs as well as increased the 
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cell membrane permeability of RAPA. On the basis of these findings, it could be 
concluded that the RDLPNPs developed in this work were promising for 
antiangiogenesis and photothermal tumor ablation. 
3.3. In Vivo Fluorescence and Photoacoustic Imaging 
We then studied the in vivo biodistribution and tumor selectivity of DLPNPs on 
a subcutaneous (s.c.) Hela tumor model. Free DiR or DLPNPs (0.05 mg DiR/kg) were 
intravenously (i.v.) administered, and fluorescence images were acquired at different 
time points postinjection. Excitation and emission wavelengths were set as 745/780 
nm for DiR. After injection, the mice were imaged with a Maestro EX in vivo 
fluorescence imaging system (CRi, Inc.) at 0, 2, 4, 6 and 12 h. From the results in 
Figure 4a, we could find that DLPNPs tended to be enriched in the tumor site over 
time, with the maximum uptake of nanoparticles in the tumor at 6 h. Control group 
revealed that the majority of free DiR was found in the liver and kidneys, suggesting 
selective tumor targeting by DLPNPs. The ex vivo fluorescent images of excised 
tissues further confirmed much higher accumulation of DLPNPs compared to free 
DiR in tumors (Figure 4b). No obvious fluorescence signals were observed in the 
heart, liver, spleen, lung and kidneys when treated with DLPNPs, while a dramatic 
accumulation of DiR was located in the liver and kidneys treated with free DiR 
(Figure 4b). Semi-quantitative analysis of biodistribution in various tissues revealed 
that the tumor accumulation of DLPNPs was 3.76-fold higher than that of free DiR at 
12 h (Figure 4c). These results demonstrated that DLPNPs could be significantly 
enriched into tumor region by the enhanced active targeting and photothermal effect 
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in the animal model. 
Compared to NIR fluorescent imaging, photoacoustics (PA) imaging was a 
newly developed biomedical imaging modality with increased imaging depth and 
improved resolution that had attracted great interest recently. It was developed on the 
base of PA effect of certain materials with strong light absorbance. Although optical 
imaging allowed whole-body imaging, PA imaging was especially helpful to visualize 
the distribution of imaging agent at tumor site. We applied PA imaging to observe the 
DLPNPs distribution in the tumor area. As shown in Figure 4d and e, the PA contrast 
at the tumor site gradually increased over time (609 ± 27, 1060 ± 56, 1850 ± 32 at 2, 4, 
6 h, respectively) comparing to that before injection (350 ± 24 at 0 h). The PA 
contrast decreased to 970 ± 57 due to the clearance of DLPNPs in vivo at 12 h post 
injection. Comparatively, upon injection (6 h), substantial PA signals were mainly 
enriched in the inner of the tumor and the tumor site of even deep to 8 mm could be 
clearly detected. These results indicated that DLPNPs could penetrate into the 
innersection of the tumor, which could result from the active targeting effect of the 
nanoparticles. Once DLPNPs was penetrated into the tumor tissue, it could generate 
substantial amount of thermal energy upon NIR irradiation. Moreover, when LPNPs 
without DiR was injected, only a slight increase of PA signal was observed due to the 
lack of FRET effect between DiR and PANI. These results indicated the FRET effect 
could also enhance the PA signals. Finally, our fluorescence and photoacoustic 
imaging results suggested that DLPNPs-mediated PTT should be carried out at 6 h 
post injection due to the maximum accumulation of DLPNPs in the tumor area at this 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
time point. 
3.4. In Vivo Photothermal Imaging  
To monitor the in vivo photothermal effect generated by RDLPNPs, an infrared 
thermal mapping apparatus was used. After 6 h intravenously injection of PBS, free 
RAPA, RLPNPs, or RDLPNPs (200 μL), respectively, mice bearing Hela tumors were 
anesthetized and exposed to an 808 nm laser at the power density of 1.5 W cm
-2
. 
Under irradiation, the tumor surface temperature of mice treated with RLPNPs or 
RDLPNPs increased from ∼30 to ∼55 ℃ within 5 min, whereas the temperature of 
the surrounding tissues increased by only 1.3 ℃ (Figure 5). In contrast, the tumor 
temperature of mice treated with PBS or free RAPA under the same NIR laser 
irradiation showed little change. These results revealed that our nanoparticles can 
rapidly raise the tumor temperature through the photothermal effect, which was able 
to kill both the tumor cells and tumor vasculature endothelial cells. 
3.5. In Vivo Combinatory Antitumor Activity  
Histopathology of various organs and tumor tissues according to H&E staining 
assay demonstrated that RDLPNPs plus NIR irradiation selectively destroyed the 
tumor cells without causing noticeable organ damage (Figure 6a and Figure S9). 
To further evaluate the antitumor efficacy of our nanoparticles, the tumor volume 
and overall survival of the tumor-bearing mice were assessed (Figure 6b). The control 
groups (PBS and free RAPA) exhibited rapid increase in tumor volume and early 
death as a function of time. Compared with free RAPA, RDLPNPs possessed 
prolonged survival time, with the gentler growth in tumor volume, although their dose 
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of RAPA was self-same. In addition, DLPNPs plus NIR laser experienced better 
antitumor efficacy than that of RDLPNPs alone. As expected, RDLPNPs plus NIR 
laser performed the best antitumor efficiency with gradual decrease in tumor volume, 
and 80% survival rate up to 48 days, owing to the combination effect of targeted drug 
delivery and PTT. Moreover, the tumors were completely eliminated, leaving the 
original tumor site with black scars on day ten after treated with RDLPNPs plus NIR 
laser (Figure 6c). These results demonstrated that RDLPNPs based combinational 
anti-angiogenesis and PTT had superior antitumor therapeutic efficacy to either 
individual therapy.  
3.6. In Vivo Antiangiogenesis Effect and Normalized Tumor Vessels 
Angiogenesis, the sprouting of new blood vessels from existing parent ones, is 
crucial for tumor growth, evasion and metastasis [55].
 
Hence, it plays a key role in the 
control of tumor progression and become a target to inhibit tumor growth [56]. Unlike 
the normal blood vessels, the constitute of tumor vasculature is abnormal, resulting in 
the formation of physiological barriers which hinder the delivery of therapeutic drugs 
into tumors [57]. Therefore, antiangiogenic imbalances in the tumor results in tumor 
vasculature normalization and thus improves nanoparticle delivery and accumulation 
in the tumor [54].
 
Combination of PTT and chemotherapy during the vascular 
normalization also exhibits synergistic effects. 
To evaluate the anti-angiogenic activity and distribution of RDLPNPs in the Hela 
tumor, blood vessels were stained by a CD-31 antibody (red color). PBS, free RAPA, 
DLPNPs or RDLPNPs was injected following the corresponding therapy experiments, 
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and the mice were sacrificed 24 h post intravenous administration (NIR laser was 
irritated at 6 h). As shown in Figure 7, mice treated with RDLPNPs with or without 
NIR laser irradiation resulted in significant increase of nanoparticles accumulation as 
well as significant decrease in the number of blood vessels in the tumor site. However, 
the number of tumor blood vessels in the mice receiving DLPNPs plus NIR laser 
treatment had little changes. Moreover, the blood vessel normalization was observed 
in the groups treated with RAPA, which was consistent with the previous reports [46, 
58, 59]. Normalization might enhance transvascular flux and improve the delivery of 
nanoparticles to the tumor. To characterize blood flow, the blood vessel area was 
quantified by the ImageJ. RDLPNPs with or without NIR laser significantly 
re-expanded the microvasculature and increased the vessel area by approximately 2.9- 
and 3.8-fold over the PBS control group, respectively. However, DLPNPs employing 
NIR laser without RAPA did not exhibit marked blood vessel normalization. These 
results demonstrated that RDLPNPs under the NIR laser effectively ablated the tumor 
vasculature and significantly improved nanoparticles delivery into the tumor. 
4. Conclusion 
In conclusion, we have successfully designed and prepared a multifunctional 
RAPA/DiR loaded lipid-conducted polymer hybrid nanoparticle system, RDLPNPs. It 
can both effectivly shutdown tumor blood vessels by RAPA and ablate tumor cells 
through FRET enhanced PTT. Notably, PANI as a receptor of FRET can effectively 
convert the NIRF energy from the donor DiR resulting in improved PTT efficacy. 
RDLPNPs selectively accumulated in tumor sites via the active targeting effect in the 
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presence of FA ligand, which can be monitored by both fluorescence and 
photoacoustic imaging. The RAPA release to the intratumoral cells was subsequently 
triggered by the enhanced photothermal effect after laser irradiation. These results 
suggested that RDLPNP was a promising photothermal drug delivery nanosystem via 
an FRET effect, which provided a new strategy to enhance photothermal efficiency 
for superior imaging-guided chemo-photothermal therapy. 
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Figures 
 
Scheme 1. (a) Construction of tumor-targeting RAPA/DiR loaded lipid-polyaniline hybrid nanoparticle 
system, RDLPNP. (b) Schematic illustration of RDLPNPs exhibiting photoacoustic and fluorescence 
imaging guided combination therapy of antiangiogenesis and enhanced photothermal performance 
mediated by FRET. 
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Figure 1. (a) TEM image of DLPNPs. (b) Photographs of DiR, PANI and DLPNPs dispersed in PBS (pH 
7.4). (c) Size distribution of DLPNPs. (d) UV-Vis absorption spectra of free DiR dissolved in methanol, 
LPNPs or DLPNPs dispersed in water. (e) Fluorescence spectra of DiR, LPNPs, and DLPNPs in the 
aqueous solution. (f) UV-Vis spectra of free DiR exposed to 1.5 W cm
-2
 808 nm photoirradiation at 
different time, respectively. (g) UV-Vis spectra of DLPNPs in aqueous solution under 1.5 W cm
-2
 
photoirradiation at different time, respectively. (h) Temperature evolution curves of PBS, aqueous solution 
of DLPNPs, LPNPs, and free DiR dissolved in methanol over a period of 5 min following exposure to the 
NIR laser (808 nm, 1.5 W cm
-2
). (i) Photothermal images of PBS, aqueous solution of DLPNPs, LPNPs, 
and free DiR dissolved in methanol over following exposure to the NIR laser (808 nm, 1.5 W cm
-2,
 5 min).  
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Figure 2. (a) Loading efficiency of RAPA in the RDLPNPs at different RAPA concentrations. (b) Loading 
content of RAPA in the RDLPNPs at different RAPA concentrations. (c) RAPA release from RDLPNPs or 
RLPNPs over time in buffers at the two different pH values indicated. (d) NIR-triggered release of RAPA 
from RDLPNPs or RLPNPs. The samples at two pH values were irradiated with an NIR laser (1.5 W cm
-2
) 
for 3 min at different time points indicated by the arrows. The data are presented as the mean ± SD (n = 3), 
*P < 0.05. 
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Figure 3. (a) Confocal images of Hela cells and HUVECs incubated with free DiO, free DiR, or 
DiO-DLPNPs with or without an NIR laser (808 nm, 1.5 W cm
-2
). Blue colors in those images represent 
DAPI-stained nuclear fluorescence. Green colors represent DiO fluorescence, which imitates the RAPA. 
Red colors represent DiR fluorescence. The scale bars are 25 μm in all confocal images. (b) Relative 
viabilities of Hela cells and HUVECs after incubation with PBS, free RAPA, LPNPs, DLPNPs, or 
RDLPNPs with or without laser irradiation (808 nm, 1.5 W cm
-2
). The data are presented as the mean ± SD 
(n = 3), *P < 0.05, **P < 0.01. (c) Confocal fluorescence images of Calcein AM/PI stained Hela cells and 
HUVECs incubated with PBS, free RAPA, DLPNPs plus NIR laser, or RDLPNP plus NIR laser, 
respectively. The scale bars are 100 μm in all confocal images. 
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Figure 4. (a) In vivo fluorescence imaging of subcutaneous Hela tumor-bearing Balb/c mice after 
intravenous injection with free DiR or DLPNPs. (b) The fluorescence imaging of dissected organs after 
intravenous injection with free DiR or DLPNPs. (c) Semi-quantitative of intensity of different organs and 
tumor. The data are presented as the mean ± SD (n = 3). **P < 0.01, significantly higher than that of free 
DiR. (d) Ultrasound (US) images and photoacoustic images of Hela tumor-bearing mice intravenously 
DLPNPs or LPNPs. The tumors are highlighted by white circle. The scale bars are 4 mm in the images. (e) 
Photoacoustic intensity of tumour tissues at diﬀerent time points. The data are presented as the mean ± SD 
(n = 3), *P < 0.05. 
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Figure 5. Photothermal images of tumor-bearing mice exposed to the NIR laser (808 nm, 1.5 W cm-2, 5 
min) after intravenous injection with PBS, free RAPA, RLPNPs, or RDLPNPs, respectively. 
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Figure 6. (a) H&E-stained different organ slices collected from mice after treatments with RLPNPs 
exposed to NIR laser (808 nm, 1.5 W cm
-2
). The scale bars are 100 μm. (b) Growth of Hela tumors in 
different groups of mice after treatment. The relative tumor volumes were normalized to their initial sizes 
on the left figure. Survival curves of mice after various treatments as indicated on the right figure. 
RDLPNPs-injected mice after PTT treatment showed 80% survival ratio over 48 days. (c) Representative 
photos of a RDLPNPs-injected mouse at day 0 before PTT treatment and at day 10 after treatment.  
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Figure 7. Antiangiogenesis effect and distribution of various formulations on the Hela xenograft tumor 
were investigated by CD-31 staining (red). Nuclei were stained blue. Green colors represent the 
fluorescence of DiR. The number denotes the average number of CD-31 positive vessels per microscopic 
field. Vessel area, quantiﬁed using ImageJ, was normalized to a PBS treated control. Five randomly 
selected microscopic fields were quantitatively analyzed on ImageJ. The data are presented as the mean ± 
SD (n = 3), **P < 0.01. The scale bar represents 50 μm. 
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